Date posted: 04/12/2020
Business location: Cambridge, MA.
Amount Funded: $60 Million
Type: Series B
Lead Investor: Boxer Capital
Participating Investor(s): Cormorant Asset Management, Casdin Capital
Note: Investors in red are new investors to this company.
Total Funding to Date: $58 Million
Company Description: “Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of targeted therapies to people with cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer.”
What funding will be used for: To advance lead program into IND-enabling studies
Further information (media):
Ten Bridge Communications
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.